Abstract t(10;11)(p12;q23) is a rare recurrent translocation involving the mixed lineage leukemia (MLL) gene translocation, most commonly seen in pediatric and young adult acute myeloid leukemia (AML), associated with early morbidity including diffuse intravascular coagulation and tumor lysis syndrome with multiorgan system failure from leukocytosis. With supportive care, first remissions are frequently attained, but patients have a high risk of relapse, extramedullary disease, and poor long-term outcomes. Introduction: Acute myeloid leukemias with MLL rearrangements are frequently associated with myelomonocytic and monoblastic/monocytic morphology, with an increased risk of leukocytosis and leukostasis-related complications. Yet, little is known regarding the clinical presentation of adult AML patients with MLL translocations based on the specific translocation partner. Patients and Methods: Two recent AML cases with t(10;11)(p12;q23) translocations are detailed, with their shared presenting symptoms highlighted, followed by a review of the current literature. Results: The specific t(10;11)(p12;q23) MLL translocation is a rare recurrent translocation partner, most commonly seen in pediatric and young adult AML. A high incidence of early morbidity from leukocytosis-related complications are frequently seen, including diffuse intravascular coagulation and tumor lysis syndrome with multiorgan system failure, even without a true leukocytosis. Conclusion: With prompt therapy and intensive supportive care first remissions are frequently attained, however, patients have a high risk of relapse, extramedullary disease, and poor long-term outcomes.
Introduction
Rearrangements involving the mixed lineage leukemia (MLL) gene on chromosome 11q23 are well described pathogenic alterations associated with myeloid and lymphoid acute leukemias. MLL rearrangements occur in infant, pediatric, and adult populations and are typically associated with an overall poor prognosis, with notable exceptions including the t(9;11) translocation which appears to confer an intermediate prognosis and the t(1;11) (q21;q23) translocation in children conferring a favorable prognosis. [1] [2] [3] [4] Although the t(9;11) translocation is the most frequent MLL alteration and occurs in approximately 30% to 50% of MLL-rearranged cases, > 120 different translocation partners have been identified to date. 5 The specific MLL fusion partner is known to impart some lineage specificity, for example, the t(4;11) (q21;q23) translocation is found predominantly in B-cell acute lymphoblastic leukemia (ALL), and other translocations, such as t(9;11) and t(10;11)(p12;q23) are overrepresented in acute myeloid leukemia (AML). [5] [6] [7] [8] Pathologically, the AMLs with recurrent MLL translocations are often characterized as myelomonocytic or monoblastic leukemias (ie, French-American-British (FAB) classification of M4 or M5), with a tendency for biphenotypic expression patterns. 9 Yet, little is known with regard to the clinical phenotype of MLL-rearranged AML patients, in particular, based on the specific translocation partner.
Two remarkable recent AML cases with t(10;11)(p12;q23) at the M.D. Anderson Cancer Center (MDACC) are herein detailed, with their shared presenting symptoms highlighted, followed by a review of the current literature.
Case 1
A 39-year-old Caucasian man with a medical history of hypothyroidism while taking levothyroxine and a history of occupational radiation exposure presented to his local emergency room for a 1-week history of shortness of breath and fevers. He described generalized fatigue for approximately 1 month. Imaging revealed a multifocal pneumonia and a complete blood count identified an increased white blood cell count of 18,300/mL, with 80% circulating blasts, a hemoglobin of 12.4 g/dL, and platelet count of 42,000/mL. He was urgently transferred to the MDACC for further evaluation and treatment. He was noted on arrival to MDACC to have evidence of chemical diffuse intravascular coagulation (DIC) with a protime of 18.3 s, partial thromboplastin time (PTT) of 45.3 s, d-dimer > 20 mg/mL, and hypofibrinogenemia of 174, and mild spontaneous tumor lysis with lactate dehydrogenase (LDH) level of 2312 IU/L, creatinine (Cr) level of 1.2 mg/dL, and uric acid level of 6.7 mg/dL. A bone marrow biopsy performed on hospital day 2 was consistent with an acute monoblastic leukemia, with 81% blasts (FAB classification AML-M5a) in a 90% hypercellular marrow with
Cytogenetics revealed a hyperdiploid clone of neoplastic cells with a t(10;11) translocation resulting in an MLL rearrangement confirmed using fluorescence in situ hybridization (FISH; Table 1 and Figure 1 ). Treatment was started with systemic chemotherapy of fludarabine 30 mg/m 2 daily for 5 days, idarubicin 10 mg/m 2 intravenous (I.V.) for 3 days, and cytarabine 1 g/m 2 I.V.
for 3 days on hospital day 6 after his diagnosis was confirmed. Before his induction regimen he was temporized with hydroxyurea 3 g orally daily starting on the day of admission and cytarabine 1 g/ m 2 I.V. once on hospital day 3.
His peak white blood cell count was 26,200/mL on hospital day 2. He had only 2 documented fevers, on the night of admission at 38. 3 C and the morning of hospital day 2 at 38.4 C. Despite resolution of his leukocytosis and disappearance of circulating blasts, and continued empiric broad-spectrum antibiotics including antibacterial, antifungal, and antiviral coverage, his shortness of breath and oxygen requirement increased, requiring 80% supplemental oxygen by hospital day 3 and mechanical ventilation on hospital day 9 ( Figure 2 (9)(q12q32),der(10) t(10;11)(p12;q23),t(10;11),þ20,þ20 [20] 46,XY,der(10)t(10;11)(p12;q21)inv(11)(q21q23),der(11)t(10;11) [4] /46,sl,der (5) t(1;5)(q11;q35) [7] /46,XY,der(10)t(10;11)(p12;q21)inv(11)(q21q23), der(11)t(1;11)(q11;p15)t(10;11) [4] /46,XY [2] At relapse: 53w55,XY,þ1,þ5,þ6,der(10)t(10;11)(p12;q21)inv(11)(q21q23), der(11)t(10;11),þ13,add (14) He was able to be extubated on day 12, and his renal function subsequently recovered and dialysis was permanently discontinued on day 20. His blood counts recovered without circulating blasts and a day 28 bone marrow biopsy confirmed a complete remission with no residual leukemic blasts according to morphology or flow cytometry, with diploid cytogenetics present in all metaphases. He was able to be discharged on hospital day 39 with no residual complications apart from a new baseline creatinine level of approximately 2. He continues on consolidation therapy and a stem cell transplant is imminently planned.
Case 2
A 20-year-old Hispanic man with no medical history was admitted to the intensive care unit of MDACC. He noted a 2 to 3 month history of progressive gingival swelling and gum irritation, and he had recently undergone a "gum stripping" dental procedure for a presumed gingivitis complicated by fevers and poor wound healing, and for which he had been prescribed oral antibiotics without relief. He was admitted to his local hospital for persistent fevers and oral pain, and a complete blood count (CBC) on admission revealed leukocytosis of 85,000/mL with circulating blasts and he was transferred to MDACC because of a concern of acute leukemia. On arrival to MDACC his CBC was 94,000/mL with 80% circulating blasts, hemoglobin 6.6 g/dL, and platelet count of 61,000/mL. He had laboratory evidence of DIC on arrival with a PT of 20.1, PTT of 62.1, fibrinogen of 157, and d-dimer > 20. Treatment was started immediately with oral hydroxyurea and I.V. cytarabine 1 g/m 2 I.V. in consideration of his leukocytosis. A bone marrow biopsy revealed an acute monocytic leukemia (M5b) with 75% monoblasts in a 95% hypercellular marrow, cytogenetics with psuedodiploid clones with an inversion 11q and t(10;11) translocation resulting in MLL rearrangement, confirmed using FISH (Table 1 Supplemental oxygen for shortness of breath with a concern for leukostasis and multifocal pneumonia was required on the day of admission, and by hospital day 3 he had progressed to acute respiratory failure requiring 100% supplemental oxygen. Imaging confirmed a multifocal infiltrate suspicious for pneumonia, diffuse alveolar infiltrates, and/or leukemic infiltrates. He required mechanical ventilation on hospital day 6, with diffuse alveolar hemorrhage identified using direct visualization in the setting of clinical DIC for which treatment was initiated with high-dose corticosteroids and aminocaproic acid infusion. He also developed tumor lysis syndrome with maximum values of LDH of 18,988, BUN of 64, Cr of 2.3, and phos of 9.1. He was supported without the need for hemodialysis. With continued empiric therapy and maximum support he slowly improved and was extubated on day 10. On day 14, he complained of abdominal pain and imaging revealed pancreatitis and splenic infarcts in the setting of increased levels of amylase and lipase of 232 IU/L and 919 U/L, respectively, also managed conservatively. All cultures obtained during his hospital stay were without growth. A day-28 recovery bone marrow biopsy confirmed a complete remission with no residual leukemic blasts according to morphology or using flow cytometry and diploid cytogenetics. He received 1 consolidation cycle with additional fludarabine, idarubicin and cytarabine, which he tolerated without toxicity or adverse events. Unfortunately, he recovered from his first consolidation cycle with relapsed disease, with recurrence of his previously identified t(10;11) with evidence of additional clonal evolution (Table 1) . He is currently receiving salvage therapy with a plan to proceed with myeloablative stem cell transplant on achievement of a second complete remission.
Discussion
The myelomonocytic (M4) and monoblastic/monocytic (M5) myeloid leukemias are often associated with greater rates of leukocytosis and extramedullary disease. AML with MLL rearrangements are frequently characterized as M4/M5 leukemias with a propensity to extreme leukocytosis, skin involvement, and central nervous system disease. Leukocytosis is typically defined as > 50,000 blasts/mm 3 and has been traditionally explained as an extreme overcrowding of large leukemic blasts in the circulation leading to hyperviscosity and vascular events. 11 However, more recent evidence describes endothelial damage occurring through abnormal cytokine profiles and altered interactions predominantly among adhesion molecules. 12 This might explain why certain leukemia subtypes are more at risk of "leukostasis"-related complications, and in particular, clarifies why this phenomenon might even be observed in leukemia patients without significant leukocytosis, such as in case 1.
The striking clinical phenotype observed in these 2 young male patients with t(10;11) MLL-rearranged AML consisted of rapid multiorgan failure including acute respiratory and renal failure, along with severe clinical DIC and tumor lysis syndrome, which developed despite appropriate and aggressive intensive chemotherapy with effective early leukoreduction.
Because of the overall rarity of this translocation, the clinical characteristics and outcome of patients with a t(10;11)(p12;q23) translocation are not well described. A historical study of 20 patients by Lillington et al, describes a cohort of younger patients with male predominance, in whom most achieve a first complete remission, yet in whom overall survival was less than 24 months and the only long-term AML survivors were those who received stem cell transplants. 9 Notably, in a recent analysis of > 1590 MLL-rearranged leukemias identified over the past decade, primarily from European centers, 120 patients were found to have a t (10;11) , and yet only 23 of them were adults (the remainder were infants and children). Our finding of 2 young adults with t(10;11) AML within the same time period at our institution was significant and inspired our review of this entity. At MDACC since 2006, we have treated 5 adults with t(10;11) and a confirmed MLL rearrangement (Table 2 ). Our analysis confirms the 
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high risk of relapsed leukemia and poor long-term survival suggested in this cytogenetically defined cohort, although 1 patient is alive and disease-free now more than 8 years after a stem cell transplant in first complete remission, suggesting that transplant in first remission should remain the goal for these patients whenever possible. The t(10;11)(p12;q23) translocation involves the MLLT10 (previously AF10) gene on chromosome 10p12, and typically arises from a complex rearrangement resulting from the insertion of chromosome 11 material, including the MLL gene, into chromosome 10p. 13 The MLLT10 gene encodes a nuclear protein that functions within the DOT1L protein network, leading to transcriptional elongation and increased histone H3 methylation signatures, and innovative therapeutic approaches including the DOT1L inhibitors provide the hope of novel and effective targeted therapy for this high-risk disease. Whether dysregulation of MLLT10 in t(10;11) patients predisposes patients to endothelial cell damage via altered cytokine signaling or adhesion interactions warrants future investigation. Finally, it is worth affirming that prompt effective treatment of the underlying leukemia with intensive cytoreductive chemotherapy, and without leukopheresis, led to resolution of the leukocytosis and reduction of the circulating leukemia blast count in both patients within 48 hours. The secondary organ dysfunction and clinical syndrome, however, took several weeks to fully improve in both patients. With continued intensive supportive care, both patients fully recovered, with both patients achieving a complete remission and with the hope of curative therapy with stem cell transplantation.
Conclusion
Acute myeloid leukemia with MLL rearrangements are frequently associated with myelomonocytic and monoblastic leukemias with an increased risk of leukocytosis and leukostasis-related complications at diagnosis. The specific t(10;11)(p12;q23) MLL translocation is a rare recurrent translocation partner, most commonly seen in pediatric patients and young adults with AML. A high incidence of early morbidity from leukocytosis-related complications are frequently seen, including DIC and tumor lysis syndrome with multiorgan system failure, even without a true leukocytosis. With prompt therapy and intensive supportive care first remissions are frequently attained, however, patients have a high risk of relapse, extramedullary disease, and poor long-term outcomes.
Clinical Practice Points
Acute myeloid leukemia with MLL rearrangements are frequently associated with myelomonocytic and monoblastic/monocytic leukemias with an increased risk of leukocytosis and leukostasisrelated complications at diagnosis. The t(10;11)(p12;q23) translocation involving MLL is a rare recurrent translocation partner, most commonly seen in pediatric patients and young adults with AML, and is associated with early morbidity including DIC and tumor lysis syndrome with multiorgan system failure from leukocytosis. With supportive care, first remissions are frequently attained, but patients have a high risk of relapse, extramedullary disease, and poor long-term outcomes.
